Pharmacogenomi cs
Technology & Theranostics & Companion Diagnostics (CDx)
Market
Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Scope: Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Growth
The Pharmacogenomics Technology, Theranostics, and Companion Diagnostics (CDx) market is rapidly expanding, driven by personalized medicine trends. The global market is projected to reach approximately $10 billion by 2026, with a CAGR of around 12%. Increasing demand for targeted therapies and enhanced patient outcomes are key factors influencing market growth.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Qiagen NV
◍ GE Healthcare
◍ Agilent Technologies
◍ F Hoffman La Roche
◍ Foundation Medicine
◍ Thermo Fisher Scientific Inc.
◍ Leica Biosystems Nussloch GmBH
◍ Pfizer
The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market features companies like Qiagen, GE Healthcare, and Thermo Fisher Scientific, which leverage genomics to optimize therapies. These firms enhance patient outcomes through tailored treatments, expanding market growth. Sales revenue highlights include:
- Thermo Fisher: ~$37 billion
- Roche: ~$58 billion
- Agilent: ~$6 billion
Request Sample Report
Market Segmentation
By Application
Oncology
Neurological Disorders
Cardiovascular Disease
Immunological Disorders
Others
By Product
◍ PCR
In-situ Hybridization
Immunohistochemistry
Sequencing
Others
Request Sample Report
Market Growth
Request Sample Report
$ X Billion USD
